Company Overview
Pulmagen Therapeutics (Inflammation) Limited is a Dissolved Private Limited Company.
Registered Address

30 C/O Mvm Partners Llp, 30 St. George Street, London, W1S 2FH
Credit Reports Available

These credit rating reports are available now:


Credit Analysts Report
Get Report >>

Standard Credit Report
Get Report >>

Basic Credit Report
Get Report >>

24/7 credit rating data feed - no UK company credit reports are updated faster

Companies House Data
Company NamePULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED
Company Number07087533
Registered Office Address30 C/O Mvm Partners Llp
 30 St. George Street
 W1S 2FH
Company CategoryPrivate Limited Company
Company StatusDissolved
Country of OriginUnited Kingdom
Incorporation Date26/11/2009
Accounting Reference Date Day30
Accounting Reference Date Month9
Accounts Next Due Date30/06/2022
Accounts Last Made Up Date30/09/2020
Accounts Account CategoryTOTAL EXEMPTION FULL
Returns Next Due Date24/12/2016
Returns Last Made Up Date26/11/2015
Previous Company NameChanged Date
ARGENTA THERAPEUTICS LIMITED16 Feb 2010
CONTINENTAL SHELF 487 LIMITED14 Jan 2010
Directors & Members
Show Resigned
Christopher Ashton - Director
(British, 64 years old, born February 1960)
Company Director - Appointed 11 January 2010
 Active
Harry Finch - Director
(British, 76 years old, born November 1948)
Research Scientist - Appointed 29 January 2010
 Active
Mary Fitzgerald - Director
(British, 64 years old, born January 1960)
Research Scientist - Appointed 29 January 2010
 Active
Ian Kent - Director
(British, 80 years old, born March 1944)
None - Appointed 29 January 2010
 Active
Colin Knox - Director
(British, 53 years old, born February 1971)
Accountant - Appointed 11 January 2010
 Active
Stephen Reeders - Director
(British, 71 years old, born May 1953)
Venture Capitalist - Appointed 23 March 2012
 Active
Hugo Slootweg - Director
(Dutch, 56 years old, born September 1968)
Venture Capitalist - Appointed 29 January 2010
 Active
Secretaries
Show Resigned
Colin Knox - Secretary
(British)
Appointed 11 January 2010
 Active
Other Company Directorships
Christopher Ashton
ACHILLES THERAPEUTICS LIMITED
ARGENTA DISCOVERY 2009 LIMITED
ETIOLOGICS LIMITED
ORCHID CELLMARK LTD
PULMAGEN THERAPEUTICS (ASTHMA) LIMITED
PULMAGEN THERAPEUTICS (HOLDINGS) LIMITED
PULMAGEN THERAPEUTICS (SYNERGY) LIMITED
PULMAGEN THERAPEUTICS LLP
SYNCONA MANAGEMENT LLP
SYNCONA PARTNERS LLP
Harry Finch
ARGENTA DISCOVERY 2009 LIMITED
PULMAGEN THERAPEUTICS (ASTHMA) LIMITED
PULMAGEN THERAPEUTICS (HOLDINGS) LIMITED
PULMAGEN THERAPEUTICS (SYNERGY) LIMITED
PULMAGEN THERAPEUTICS LLP
PULMOCIDE LIMITED
RIBOTARGETS HOLDINGS LIMITED
TWOFOLD FIRST SERVICES LLP
Mary Fitzgerald
No companies found
Ian Kent
ARGENTA DISCOVERY 2009 LIMITED
INNOVATA LIMITED
PULMAGEN THERAPEUTICS (ASTHMA) LIMITED
PULMAGEN THERAPEUTICS (HOLDINGS) LIMITED
PULMAGEN THERAPEUTICS (SYNERGY) LIMITED
Colin Knox
AMDOCS (UK) FINANCING LIMITED
AMDOCS (UK) LIMITED
AMDOCS MANAGEMENT LIMITED
ARGENTA DISCOVERY 2009 LIMITED
ETIOLOGICS LIMITED
IGNIS UK INVESTMENT LIMITED
PULMAGEN THERAPEUTICS (ASTHMA) LIMITED
PULMAGEN THERAPEUTICS (HOLDINGS) LIMITED
PULMAGEN THERAPEUTICS (SYNERGY) LIMITED
PULMAGEN THERAPEUTICS LLP
Stephen Reeders
BEACON ENDOSCOPIC LIMITED
DOMANTIS LIMITED
MUDDY RIVER INVESTMENTS LIMITED
MVM (CIP) (NO.2) LIMITED
MVM (GP) (NO.2) LIMITED
MVM (GP) (NO.3) LIMITED
MVM (GP) (NO.4B) LIMITED
MVM (GP) (NO.5A) LIMITED
MVM (GP) (NO.5B) LIMITED
MVM (GP) LIMITED
MVM EXECUTIVE LTD
MVM LIMITED
MVM PARTNERS LLP
OXXON THERAPEUTICS LIMITED
PULMAGEN THERAPEUTICS (ASTHMA) LIMITED
PULMAGEN THERAPEUTICS (HOLDINGS) LIMITED
SANGAMO THERAPEUTICS UK LTD
XENTION LIMITED
Hugo Slootweg
No companies found
Balance Sheet Unlock full report
Accounts Date 30-Sep-2020 31-Mar-2011 31-Mar-2010
Balance Sheet
Fixed Assets 3,000 3,000 3,000
Current Assets 2,121,000 2,121,000 3,215,000
Creditors Due Within One Year 287,000 287,000 97,000
Working Cap 1,834,000 1,834,000 3,118,000
Total Assets Less Current Liabilities 1,837,000 1,837,000 3,121,000
Long-term Liabilities 0 0 0
Net Assets 1,837,000 1,837,000 3,121,000
Share Capital & Reserves
Share Cap 412,000 412,000 412,000
Profit & Loss Reserves -1,913,000 -1,913,000 -629,000
Other Reserves 3,338,000 3,338,000 3,338,000
Shareholders Funds 1,837,000 1,837,000 3,121,000
Common Size Financial Analysis Unlock full report
Accounts Date 30-Sep-2020 31-Mar-2011 31-Mar-2010
Tangible Fixed Assets - - -
Fixed Assets 0.1% 0.1% 0.1%
Stocks Inventory 0.0% 0.0% 0.0%
Debtors 8.5% 8.5% 10.8%
Cash Bank In Hand 91.3% 91.3% 89.1%
Current Assets 99.9% 99.9% 99.9%
Creditors Due Within One Year 13.5% 13.5% 3.0%
Net Current Assets Liabilities 86.3% 86.3% 96.9%
Creditors Due After One Year 0.0% 0.0% 0.0%
Accruals Deferred Income - - -
Provisions For Liabilities Charges - - -
Net Assets Liabilities Including Pension Asset Liability 86.5% 86.5% 97.0%
Called Up Share Capital 19.4% 19.4% 12.8%
Share Capital Allotted Called Up Paid 19.4% 19.4% 12.8%
Profit Loss Account Reserve -90.1% -90.1% -19.5%
Shareholder Funds 86.5% 86.5% 97.0%
Capital Employed - - -
Total Assets Less Current Liabilities 86.5% 86.5% 97.0%
Financial Ratio Analysis Unlock full report
Accounts Date 30-Sep-2020 31-Mar-2011 31-Mar-2010
Liquidity Ratio 7.4 7.4 33.1
Solvency Ratio 7.4 7.4 33.2
Reserves to Assets -0.9 -0.9 -0.2
Secured Creditors Unlock full report
Mortgages Charges 0
Mortgages Outstanding 0
Mortgages Part Satisfied 0
Mortgages Satisfied 0
Assets and Debt Analysis Unlock full report
Accounts Date 30-Sep-2020 31-Mar-2011 31-Mar-2010
Assets 2,124,000 2,124,000 3,218,000
Debt 287,000 287,000 97,000
Net Assets/Debt 1,837,000 1,837,000 3,121,000
Public Record Information Unlock full report
Exact Court Judgements
Period of Months Last 12m 13-24m 25-36m 37-48m 49-60m 61-72m
Number of Exact CCJS X Y Y X X Y
Value of Exact CCJS YXY YK S S X KX
Supplier Credit Limits Unlock full report
Date Sector Notified Amount Terms
XK-SXY XKXYXK SXSKXYXK £X,000 XS XYSKS
SK-SYY SKXYXKYKKY KSXX KKXXYXS £YY,000 YS XYSKS SK YXXSXS
YK-SXY XKXYXYYK SXSXYXK £SX,000 XS XYSKS
Payment Records Unlock full report
Payment Records from it's suppliers' company ledger show how a company is paying its suppliers

Payment Analysis

Total Invoices Paid Before
30 days due		 Paid After
30 days due		 Owing Before
30 days due		 Owing after
30 days due
XYX SX K YX X
Company Valuation Analysis Unlock full report

Going Concern Valuation

The going concern valuations value the company on the basis that it continues to trade without the threat of liquidation for the foreseeable future. These valuations are primarily profit and cashflow based.

Valuations Valuation Measures
Estimated High Value £XSI,000 Retained Profit £YX,000
Estimated Mid Value £YY,000 EBIT £SY,000
Estimated Low Value £X,000 EBITDA £SSX,000

Liquidation Valuation

The liquidaton valuation values the company as if it were to cease trading and assets were subject to rapid disposal to cover liabilities. This valuation is primarily asset based.

Valuations Valuation Measures
Estimated High Value £XY,000 Total Assets £XIX,000
Estimated Mid Value £Y,000 Net Assets £YX,000
Estimated Low Value £S,000 Tangible Equity £SX,000

The above valuations are based on our own algorithms and take no account of many factors that can influence actual valuations realized and should not therefore be assumed to be accurate.
Credit Status Checklist Unlock full report
Business Growth Please purchase a report to see true comments
EBITDA Purchase a report to see true comments
Dividends Please purchase a report to see true comments about this company
Retained Profits Retained Profits for this company
Debt Interest Debt Interest for this company
Cash Flow Cash Flow for this company
CCJs CCJs for this company
Age of Company Age of Company for this company
Solvency Solvency for this company
Secured Creditors Secured Creditors for this company
Ownership Ownership for this company


First Report Score: (0-10) X
Financial Status Guide:
10 Very Strong
9 Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical

Risk Score Trend

Risk Rating Unlock full report

This is the credit risk assessment used by one of the top UK credit reference agencies.

Risk Score (1-100) X
Risk Band Description XXMXMXMX SISX
Risk Assessment Meeting of Creditors
Credit Rating XSKX
Altman Z Score Credit Risk Rating Unlock full report

There have been many bankruptcy predictors developed, however none has been so thoroughly tested and broadly accepted as the Altman Z-Score.

Z Score X
Risk Band XY
Risk Band Description The Z Score is not used for small companies where full accounts are not filed because profit and loss account items are required to calculate the score.

Z Score Bands

1 Low Risk 3.00 and above
2 Caution 2.63 - 2.99
3 Risk of Failure within 2 years 1.24 - 2.62
4 High Probability Failure Below 1.24
Other Business around W1S 2FH
MVM (GP) LIMITED
30 St. George Street, London, W1S 2FH
MVM INTERNATIONAL LIFE SCIENCES NO.1 LIMITED PARTNERSHIP
30 ST GEORGE STREET, LONDON, W1S 2FH
MVM LIFE SCIENCE (GP) (NO.2) LLP
30 St. George Street, London, W1S 2FH
MVM (GP) (NO.4A) LIMITED
38 WIGMORE STREET, FOURTH FLOOR OFFICES, SUITE 2, LONDON, W1S 2FH
MVM (GP) (NO.4B) LIMITED
38 WIGMORE STREET, FOURTH FLOOR OFFICES, SUITE 2, LONDON, W1S 2FH
MVM PARTNERS LLP
38 38 WIGMORE STREET, FOURTH FLOOR OFFICES, SUITE 2, LONDON, W1S 2FH
MVM (GP) (NO.5B) LIMITED
38 WIGMORE STREET, FOURTH FLOOR OFFICES, SUITE 2, LONDON, W1S 2FH
UK MEDICAL VENTURES FUND NO. 1
30 ST GEORGE STREET, LONDON, W1S 2FH
LETZDREAM FOUNDATION
KEMP HOUSE, 160 CITY ROAD, LONDON, W1S 2FH
MUDDY RIVER INVESTMENTS LIMITED
C/O Mvm Partners Llp, 30, St. George Street, London, W1S 2FH
Document Filings
Final Gazette dissolved via voluntary strike-off
First Gazette notice for voluntary strike-off
Application to strike the company off the register
Confirmation statement made on 26 November 2020 with no updates
Registered office address changed from C/O Dr C P Ashton Stevenage Bioscience Catalyst Gunnels Wood Road Stevenage SG1 2FX England to 30 C/O Mvm Partners Llp 30 st. George Street London W1S 2FH on 28 January 2020
Previous accounting period extended from 31 March 2019 to 30 September 2019
Confirmation statement made on 26 November 2019 with no updates
Confirmation statement made on 26 November 2018 with updates
Confirmation statement made on 26 November 2017 with no updates
Registered office address changed from C/O Achilles Therapeutics Stevenage Bioscience Catalyst Gunnels Wood Road Stevenage SG1 2FX England to C/O Dr C P Ashton Stevenage Bioscience Catalyst Gunnels Wood Road Stevenage SG1 2FX on 14 July 2017
Registered office address changed from C/O Mvm Life Science Partners Llp 6 Henrietta Street London WC2E 8PU to C/O Achilles Therapeutics Stevenage Bioscience Catalyst Gunnels Wood Road Stevenage SG1 2FX on 7 March 2017
Confirmation statement made on 26 November 2016 with updates
Annual return made up to 26 November 2015 with full list of shareholders
Registered office address changed from The Coach House Grenville Court Britwell Road Burnham Slough SL1 8DF to C/O Mvm Life Science Partners Llp 6 Henrietta Street London WC2E 8PU on 17 July 2015
Annual return made up to 26 November 2014 with full list of shareholders
Memorandum and Articles of Association
Annual return made up to 26 November 2013 with full list of shareholders
Director's details changed for Hugo Alexander Slootweg on 1 December 2013
Terms and Conditions Cancellations Contact Us

In using this service you agree to the Terms and Conditions

© 2024 Check Free